Adjuvant therapies for management of hemorrhagic shock: a narrative review
Authors' conclusion
Promising molecules, some of which are already used in humans for other indications, give us hope for human clinical trials in the field of hemorrhagic shock in the near future.
Study context
- Population
- Severe trauma patients with hemorrhagic shock (initial resuscitation, incl. out-of-hospital settings)
- Comparison
- Niacin vs Thiazolidinediones vs Prolyl hydroxylase domain inhibitors vs O-GlcNAcylation stimulation vs Histone deacetylase inhibitors vs Adenosine-lidocaine-magnesium solution
Main finding
As reported in the abstract
- Six adjuvant treatments that may help cells cope with tissue hypoxia reviewed: biological mechanism and preclinical and human clinical data in hemorrhagic shock
Original publication
Adjuvant therapies for management of hemorrhagic shock: a narrative review. Crit Care. Published 29 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →